Multicenter Randomized Controlled Trial to Compare the Outcome of Conservative Triple Target Treatment With EMG-Biofeedback in Chronic Obstipation

Overview

Previous studies revealed only a low evidence for the various biofeedback methods and pelvic floor exercises for treatment of chronic obstipation. The number of randomized controlled trials is low with in part significant systemic deficiencies. However, the results from the previous study with 3T treatment in patients with obstructed defecation syndrome (ODS) are so promising that a further randomized controlled trial appears useful to demonstrate a higher degree of evidence. The purpose of this study is to determine whether triple target treatment (3T) or EMG-Biofeedback alone are effective in the treatment of chronic obstipation and if the duration of treatment (3, 6 or 9 months) influence the efficacy.

Full Title of Study: “Triple Target Treatment (3T) Combining Amplitude Modulated Middle Frequency (AM-MF) Stimulation With Electromyography (EMG)EMG-Biofeedback Versus EMG-Biofeedback in Chronic Obstipation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: May 2014

Detailed Description

Methods in this parallel-group randomized multicenter study with blinded observer we enroll 140 patients with chronic obstipation. The study is divided into two trials. After three months the first trial is completed and can be extended directly into the second trial (completed after 12 months) after an interim analysis. Primary endpoints are changes from baseline to three and twelve months in the Altomare ODS Score.

Interventions

  • Device: Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation
  • Device: EMG-biofeedback alone

Arms, Groups and Cohorts

  • Experimental: Triple Target Treatment
    • In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
  • Active Comparator: EMG-biofeedback alone
    • In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.

Clinical Trial Outcome Measures

Primary Measures

  • Altomare ODS Score in its validated form after 3 and 12 months, compared to baseline.
    • Time Frame: 3 months

Secondary Measures

  • Constipation severity instrument (CSI) in adapted German form after 3 and 12 months, compared to baseline.
    • Time Frame: 3 and 12 months
  • Modified Wexner Incontinence Score after 3 and 12 months, compared to baseline
    • Time Frame: 3 and 12 Months
  • Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QoL) after 3 and 12 months compared to baseline, as well as between the two treatment groups over the course of time as compared to baseline.
    • Time Frame: 3 and 12 months
  • Hinton Test after 3 and 12 months
    • Time Frame: 3 and 12 months
  • Cleveland Clinic Incontinence Score (CCS) in its validated German form after 3 and 12 months, compared to baseline
    • Time Frame: 3 and 12 months
  • Adapted Vaizey score after 3 and 12 months compared to baseline
    • Time Frame: 3 and 12 months
  • International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) applied to patients with urine incontinence after 3 and 12 months, compared to baseline.
    • Time Frame: 3 and 12 months

Participating in This Clinical Trial

Inclusion Criteria

  • All Patients with chronic obstipation (Rom criteria II) Exclusion Criteria:

  • Chronic inflammatory bowel disease, systemic peripheral neuropathy (MS, diabetes), disorders of enteric nervous system (Hirschsprung disease, chagas, IND, myopathy desmosis coli), idiopathic megacolon/megarectum, patients with mental or intellectual deficits.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • dr. schwandner
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: dr. schwandner, Head of Coloproctology – University of Giessen
  • Overall Official(s)
    • Thilo Schwandner, Dr., Principal Investigator, University of Giessen
  • Overall Contact(s)
    • Thilo Schwandner, Dr., 00496419944701, t.schwandner@web.de

References

Schwandner T, Hecker A, Hirschburger M, Hecker M, Kierer W, Padberg W. Does the STARR procedure change the pelvic floor: a preoperative and postoperative study with dynamic pelvic floor MRI. Dis Colon Rectum. 2011 Apr;54(4):412-7. doi: 10.1007/DCR.0b013e318205ddda.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.